Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 5Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 13fludarabine 11Mycophenolic Acid 9Busulfan 8fludarabine phosphate 7Tacrolimus 7pirtobrutinib 6Whole-Body Irradiation 6Rituximab 6Melphalan 6Imatinib Mesylate 5Bone Marrow Transplantation 5ponatinib 4Mesna 4Granulocyte Colony-Stimulating Factor 4Azacitidine 4venetoclax 3nilotinib 3lintuzumab 3Stem Cell Transplantation 3Sirolimus 3Platelet Transfusion 3Methotrexate 3Cytarabine 3Cyclosporine 3Alemtuzumab 3vosaroxin 2ruxolitinib 2ibrutinib 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × cedazuridine × Other hematologic neoplasm × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡